Caremo Honored in The 3rd KPMG China BioTech Innovation Top 50 Enterprises

The 3rd KPMG China BioTech Innovation Top 50 Enterprises selection initiative, jointly launched by KPMG China, Hainan International Medical Innovation Consortium Foundation, and Suzhou BioBay, officially unveiled its results today after six months of multi-stage screening, on-site evaluations, and expert reviews. Kemore Pharma secured its position on this prestigious list by demonstrating outstanding technological innovation capabilities, full-industry-chain service competencies, and industry influence. This accolade signifies high recognition of Caremo's persistent dedication to pharmaceutical R&D excellence.

KPMG BioTech Innovation Top 50: Empowering Industry Innovation Through Authoritative Selection

This year's selection expanded its coverage across biopharmaceuticals, cell and gene therapy, medical technology, in vitro diagnostics, CRO/CMO, TCM innovation, and AI-driven drug discovery. The judging panel comprised authoritative representatives from academia, investment communities, multinational pharmaceutical corporations, and regulatory agencies. Enterprises were rigorously assessed across six core dimensions: technological and product leadership, pipeline diversity, proportion of original innovations, team expertise, industrialization potential, capital market engagement, and financial health—comprehensively evaluating their innovation capabilities, growth potential, and societal value.

Guided by the principle of "professional evaluation, ecosystem empowerment, and future leadership," the initiative ensures comprehensive, impartial, and authoritative benchmarking to propel China's biotech innovation ecosystem forward.

Caremo focuses on full-cycle empowerment for industry advancement. Centered on "end-to-end enablement," Caremo services span preclinical research, CMC development, clinical trials, customizable solutions, and drug incubation investments, accelerating the translation from target discovery to commercialization for global biotech and pharmaceutical partners.

As a CRO committed to delivering one-stop R&D solutions, Caremo continuously advances technological innovation and industrial collaboration, achieving breakthroughs in complex formulation development. Moving forward, the company will accelerate technological upgrades, enhance R&D efficiency and precision, and collaborate with ecosystem partners through open platforms and diversified models to drive high-quality development in China's biopharmaceutical industry.